The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 357:2201-2203 November 22, 2007 Number 21
NextNext

More on Cetuximab in Head and Neck Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Bonner, J. A.
-PubMed Citation
To the Editor: The study by Bonner et al. (Feb. 9, 2006, issue)1 reports a survival advantage with the addition of concurrent cetuximab to radiotherapy in patients with advanced head and neck cancer. In addition, cetuximab improved locoregional control but had no effect on distant metastases.

In this study, the method used to evaluate locoregional control differed from methods used in other major clinical trials. The authors used the Kaplan–Meier method to estimate locoregional control, defining its duration as the "time from randomization until the first documented progression or recurrence of locoregional disease or until death from any cause." This . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.